<DOC>
	<DOCNO>NCT01657045</DOCNO>
	<brief_summary>This study investigate safety efficacy use JVS-100 accelerate wound heal reduce scar formation subject receive surgical incision ( `` sternotomies '' ) cardiovascular surgery . Twenty-five ( 25 ) subject receive median sternotomy 16 - 25 cm process cardiothoracic surgery enrol consecutively follow 6 month post-dosing . Three cohort approximately 8 subject enrol , within cohort subject randomize 3:1 receive single set needle-free dermal injection either JVS-100 placebo . JVS-100 placebo deliver along edge sternal wound use needle-free injection device FDA-clearance subcutaneous injection .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Dermal Injections JVS-100 Given Adults Receiving Median Sternotomy</brief_title>
	<detailed_description />
	<criteria>Men woman 40 80 year age inclusive Patients undergo median sternotomy cardiac surgical procedure , incision length 1625 cm Subject must able understand study procedure , agree participate study program , voluntarily provide write informed consent Subjects BMI 25 40 kg/m2 All subject age 50 old must Fecal occult blood test ( FOBT ) fecal immunochemical test ( FIT ) negative within last year colonoscopy within last 10 year Women age 40 65 must Papanicolaou ( PAP ) test negative within last 5 year unless total hysterectomy previously perform benign disease Women age 40 old must mammogram negative within last year All diabetic subject must ophthalmologic exam within last year show active proliferative retinopathy . Subject schedule mechanical device assistance , heart transplantation Class IV heart failure Subject acute myocardial infarction le 3 day prior schedule surgery Subject undergo urgent bypass surgical procedure History scleroderma , connective tissue disorder , rheumatoid arthritis , ankylose spondylitis systemic lupus erythematosus ( SLE ) Pregnant lactate woman subject childbearing potential protected effective method birth control Life expectancy &lt; 1 year Diabetes mellitus HgbA1C &gt; 10.5 % test within 2 week prior surgery Existing scar area study Subject receive cytotoxic agent history chest radiation therapy and/or likely require treatment 30 day period follow surgery , include use radiation diagnostic imaging , e.g. , PET Scan , CT SCAN , Fluro , Myocardial Perfusion ( SPECT ) . Chest tattoo sternum , breast implant , prior mastectomy lumpectomy Subject plan use alternative/accessory wound heal treatment Infection treat systemic antibiotic within 3 day schedule surgery Chronic kidney disease ( stage 5 ) require dialysis Significant Hepatic disease Significant know infected HBV , HIV HCV Clinically significant elevation decrease PT/PTT/INR/WBC Concurrent medical condition associate prolonged recovery surgery ( e.g. , significant respiratory disease , high risk ventilator dependence , current use systemic steroid ) Subject cognitive impairment Any patient history cancer exception : 1 ) The cancer limit curable nonmelanoma skin malignancy ; 2 ) The cancer remove successful tumor resection , without radiation chemotherapy treatment , 5 year prior enrollment study without recurrence . Men unwilling agree barrier contraception unless previously receive vasectomy Presence condition , opinion investigator , might compromise aspect trial Previous treatment angiogenic growth factor stem cell therapy within 1 year Participation another clinical trial investigational agent previous 30 day History drug alcohol abuse past year</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Cicatrix</keyword>
	<keyword>Wound heal</keyword>
</DOC>